CFTR Lifecycle Map—A Systems Medicine Model of CFTR Maturation to Predict Possible Active Compound Combinations
Different causative therapeutics for CF patients have been developed. There are still no mutation-specific therapeutics for some patients, especially those with rare CFTR mutations. For this purpose, high-throughput screens have been performed which result in various candidate compounds, with mostly...
Main Authors: | Liza Vinhoven, Frauke Stanke, Sylvia Hafkemeyer, Manuel Manfred Nietert |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/14/7590 |
Similar Items
-
Phenotyping of Rare <i>CFTR</i> Mutations Reveals Distinct Trafficking and Functional Defects
by: Marjolein Ensinck, et al.
Published: (2020-03-01) -
Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
by: Virginia Spanò, et al.
Published: (2021-02-01) -
Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
by: Onofrio Laselva, et al.
Published: (2019-10-01) -
Regulatory crosstalk by protein kinases on CFTR trafficking and activity
by: Carlos Miguel eFarinha, et al.
Published: (2016-01-01) -
Airway Inflammation and Host Responses in the Era of CFTR Modulators
by: Karen Keown, et al.
Published: (2020-09-01)